Ligand-bound integrin αvβ6 internalisation and trafficking

Area of Science:

• Cell Biology
• Molecular Medicine
• Biochemistry

Background:

• Integrin αvβ6 is minimally expressed in healthy tissues but significantly upregulated in diseases like cancer and fibrosis.
• Integrin surface expression and function are regulated by endocytosis and trafficking, yet αvβ6 regulation remains poorly understood.
• Targeting αvβ6 is a key strategy for developing novel therapeutics for cancer and fibrosis.

Purpose of the Study:

• To elucidate the endocytic pathways and regulatory mechanisms governing integrin αvβ6.
• To identify genes involved in αvβ6 internalization and trafficking.
• To assess the impact of αvβ6 endocytosis inhibition on cell migration and therapeutic potential.

Main Methods:

• Development of a flow cytometry assay to quantify ligand-bound αvβ6 endocytosis.
• Performed an siRNA screen to identify genes regulating αvβ6 internalization.
• Investigated αvβ6 colocalization with endosomal markers and assessed recycling dynamics.

Main Results:

• Identified 15 genes, primarily involved in dynamin-dependent pathways, that significantly decrease αvβ6 endocytosis.
• Inhibition of dynamin-dependent pathways (clathrin and caveolin) substantially reduced αvβ6-dependent cell migration.
• Ligand-bound αvβ6 resides in Rab11-positive endosomes for up to 6 hours, with 60% recycled to the surface by this time, and shows no degradation within 48 hours.

Conclusions:

• Integrin αvβ6 undergoes dynamin-dependent endocytosis and recycling, with ligand binding influencing its surface presence and potentially therapeutic delivery.
• These findings are critical for designing effective αvβ6-targeted therapies for cancer and fibrosis, considering the ligand-bound state upon recycling.
• Understanding αvβ6 trafficking dynamics provides insights into optimizing therapeutic strategies and payload delivery.